Updating results

206 results

Sort: Relevance | Date

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

This guidance has been updated and replaced by NICE technology appraisal guidance 531.

Technology appraisal guidance Published June 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

Technology appraisal guidance Published August 2017

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

This guidance has been updated and replaced by NICE technology appraisal guidance 555.

Technology appraisal guidance Published March 2018

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

This guidance has been updated and replaced by NICE technology appraisal guidance 616.

Technology appraisal guidance Published December 2017